DeepMed Research

ICAHN School of Medicine At Mount Sinai

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1963-01-01

Employees: 5K

Market Cap: -

Website: http://www.mssm.edu

Clinical Trials

Upright MRI for Prostate Cancer Screening

Recruiting

Conditions: Elevated PSA
Elevated Prostate Specific Antigen
Prostate Cancer

Interventions: Device: Upright MRI
Device: Standard MRI

First Posted Date: 2018-03-23

Last Posted Date: 2024-10-28

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 550

Registration Number: NCT03474913

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Asthma and Obesity: Observational

Completed

Conditions: Asthma
Obesity

First Posted Date: 2018-03-09

Last Posted Date: 2021-05-06

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 333

Registration Number: NCT03460834

Locations: 🇺🇸
University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

SURE 18 Registry -Asahi Chikai Black 18 in LVO Stroke

Completed

Conditions: Occlusive Stroke

Interventions: Device: Asahi Chikai Black 18 neurovascular guidewire

First Posted Date: 2018-02-19

Last Posted Date: 2020-03-10

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 100

Registration Number: NCT03438565

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Assessment of Portal Hypertension With Multiparametric MRI

Completed

Conditions: Portal Hypertension
Clinically Significant Portal Hypertension

Interventions: Procedure: mpMRI
Procedure: ARFI US

First Posted Date: 2018-02-19

Last Posted Date: 2023-03-06

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 69

Registration Number: NCT03436550

Locations: 🇺🇸
Mount Sinai Medical Center, New York, New York, United States

Nutrient Mixtures and Neurodevelopment

Completed

Conditions: Neurodevelopment

Interventions: Other: Nutrient mixtures

First Posted Date: 2018-02-05

Last Posted Date: 2019-10-14

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 329

Registration Number: NCT03420872

Locations: 🇲🇽
National Institute of Public Health, Mexico City, Mexico

Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: Brodalumab

First Posted Date: 2018-01-18

Last Posted Date: 2021-03-10

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 39

Registration Number: NCT03403036

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Eliminating Hepatitis C Virus

Completed

Conditions: Hepatitis C
Type2 Diabetes
HIV

First Posted Date: 2018-01-17

Last Posted Date: 2021-03-24

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 52

Registration Number: NCT03401697

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Computerized Cognitive Intervention in the Oldest-Old

Not Applicable

Completed

Conditions: Dementia
Cognition

Interventions: Behavioral: Control-games
Behavioral: CogniFit™

First Posted Date: 2018-01-12

Last Posted Date: 2018-01-12

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 69

Registration Number: NCT03397498

Locations: 🇺🇸
Jewish Home Lifecare, New York, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinia, New York, New York, United States

Reducing the Duration of Untreated Psychosis in the United States

Completed

Conditions: First Episode Psychosis (FEP)
At Risk Mental State (ARMS)

First Posted Date: 2017-12-12

Last Posted Date: 2021-12-14

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 94

Registration Number: NCT03369730

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Trustees of Boston University, Boston, Massachusetts, United States
🇺🇸
Research Foundation/City University of New York (CUNY) on behalf of CUNY Graduate School, New York, New York, United States

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

Phase 2

Completed

Conditions: Alopecia Areata

Interventions: Drug: Dupilumab
Drug: Placebo

First Posted Date: 2017-12-02

Last Posted Date: 2022-09-13

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 60

Registration Number: NCT03359356

Locations: 🇺🇸
The Rockefeller University Laboratory for Investigative Dermatology, New York, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy